Monthly Archives: June 2011

Planning Beyond the Petri Dish: A Pfizer Case Study

By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Posted in Emerging Markets, Global, R&D | Tagged , , , , , , , | Leave a comment

Study Points to Dramatic Drop In R&D Expenditure

By Guest Blogger | Published: June 29, 2011
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Tagged , , , , | 1 Comment

The Most Influential Pharma Leader Or Institution?

By Julian Upton | Published: June 28, 2011
Ahead of Pharm Exec’s 30th Anniversary Issue later this year, we are assembling a list of pharma leaders who have made the most impact on the industry. Which individual(s) or institution(s) do you think has had the most influence of the industry in the last 10–30 years? Please leave a comment in the box below or drop [...]
Posted in People, leadership | Tagged , , , | 9 Comments

Europe: New Vision, Old Ideas

By Guest Blogger | Published: June 27, 2011
Europe: New Vision, Old Ideas The European industry is making saintly noises about collaboration, but vestiges of the old dogma remain, says Reflector. If you want to know what the Vatican is thinking, a pontifical high mass is a good place to start. If you want to know what the European pharmaceutical industry is thinking, you can [...]
Posted in Europe, Guest Blog, Regulatory | Tagged , , , , | Leave a comment

Supreme Court Strikes down Vermont Law, Upholds Rep Free Speech

By Reid Paul | Published: June 24, 2011
June 23rd was a good day for the pharmaceutical industry. The Supreme Court released two decisions that largely went pharma’s way. There was much rejoicing across the industry, and for good reason, business as usual won out. In PLIVA v. Mensing, the Court ruled that generic drug companies should comply with federal regulations instead of [...]
Posted in Legal | Tagged , , , | Leave a comment